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Letter to the EditorLong  term effect  of telmisartan  in HIV-positive
male patients  with  high  blood  pressureSeveral studies have found that HIV+ people are at increased
risk for premature cardiovascular disease and endothelial
damage compared with HIV− population.1 As for the gen-
eral population also for HIV+ patients high blood pressure
(BP) is one of the most preventable causes of cardiovascular
disease morbidity and mortality. In recent years, atten-
tion has focused on anti-hypertensive (AH) drugs that block
the renin–angiotensin system, because these drugs have a
multiple favourable effect on mortality and morbidity. Specif-
ically telmisartan showed agonistic effect on PPAR gamma.
This ﬁnding is particularly relevant in HIV+ patients who
have higher incidence of metabolic disorder related with
HIV infection and combined antiretroviral therapy (cART). In
HIV population limited data showed the effect of AH ther-
apy and some trials with telmisartan are available in this
population.2–4 Moreover in studies involving HIV− patients it
was previously demonstrated that telmisartan had the higher
long term efﬁcacy. The aim of this study was to evaluate
the long term effect of AH therapy with telmisartan over a
period of 144 weeks in HIV+ patients by the means of both
high blood pressure control and amelioration of metabolic
abnormalities.
This was a prospective observational study involving 13
Caucasian male HIV+ patients having been in cART and newly
diagnosed with high blood pressure enrolled from July 2009 to
July 2010 and longitudinally followed for 3 years.
All patients were treated with telmisartan at the dose of
80 mg  administered orally once a day and were controlled
every 6 month for 3 years. Participants were asked to adhere
to their usual diet and lifestyle during the study.In 144 weeks of treatment we  did not observe any adverse
event, or drop out and adherence to antihypertensive therapy
as well as that to the cART was complete.Analysis of the data has shown a clear improvement in
blood pressure, the difference between the baseline value and
week 144 was 9.2 ± 3.4 mmHg  (p = 0.006) for Systolic BP and
11.9 ± 2.9 mmHg  (p = 0.001) for Diastolic BP. We  also observed
an improvement of the main metabolic parameters, in partic-
ular HDL-cholesterol signiﬁcantly increased between baseline
and 144 weeks (p = 0.011; delta T0–T144 = 9.0 ± 2.3), with a statis-
tically signiﬁcant reduction of the ratio cholesterol total/HDL
(p = 0.011). A signiﬁcant reduction of triglycerides was also
observed during the follow-up period (p = 0.021). Total choles-
terol and LDL-cholesterol also decreased, although this ﬁnding
did not reach the statistical signiﬁcance.
In addition we observed an improvement of the main
inﬂammatory markers with a signiﬁcant reduction of
ESR (p = 0.021), a signiﬁcant reduction of microalbuminuria
(p = 0.041) and a signiﬁcant reduction of cystatin-C (p = 0.041);
ﬁnally CRP also decreased but the differences was not statis-
tically signiﬁcant (Table 1).
Throughout the course of the trial the CD4 absolute
number and CD4 percentage signiﬁcantly improved (p = 0.018
and p < 0.001, respectively); with signiﬁcant improvement of
CD4/CD8 ratio between 0.6 ± 0.4 to 0.8 ± 0.4 (p < 0.001) at 144
weeks and the remarkable no virological failure (HIV-RNA
>400 cp/mL) was observed in patients during the follow-up
period (Table 1). In conclusion telmisartan was effective in
improving hypertension for 144 weeks. It determined the
improvement of lipid proﬁle, cystatin C and microalbumin-
uria, markers of renal function and cardiovascular risk.5
Telmisartan does not interfere with cART, not interfering with
the recovery immunological in HIV+ patients. Telmisartan,
thus, has a long term efﬁcacy and excellent tolerability. There-
fore it should be considered the ﬁrst choice in the treatment
of hypertension in HIV+.
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Table 1 – Mean ± standard deviation of parameters according to different phase of the follow-up.
Variable Baseline 24 weeks 48 weeks 72 weeks 96 weeks 120 weeks 144 weeks p-Valuea
Systolic blood
pressure (mmHg)
141.5 ± 10.1 126.5 ± 10.3 131.9 ± 10.7 130.0 ± 14.9 134.2 ± 9.7 130.4 ± 10.1 132.3 ± 7.8 0.006
Diastolic blood
pressure (mmHg)
91.5 ± 9.2 82.3 ± 6.0 83.8 ± 9.8 78.1 ± 9.2 83.8 ± 9.2 81.5 ± 6.2 79.6 ± 8.5 0.001
Total cholesterol
(mg/dL)
225.85 ± 45.4 213.2 ± 51.2 218.3 ± 43.8 214.3 ± 53.7 208.6 ± 50.9 203.4 ± 37.0 206.7 ± 47.4 0.403
HDL-cholesterol
(mg/dL)
37.6 ± 8.9 42.8 ± 14.5 43.9 ± 17.2 43.6 ± 13.7 43.5 ± 15.3 45.1 ± 13.7 46.6 ± 12.9 0.011
LDL-cholesterol
(mg/dL)
133.8 ± 45.6 121.5 ± 47.8 127.4 ± 37.2 129.3 ± 53.8 121.3 ± 43.4 114.3 ± 34.7 121.5 ± 41.0 0.073
Total cholesterol/HDL
ratio
6.2  ± 1.4 5.3 ± 1.4 5.4 ± 1.6 5.3 ± 1.9 5.2 ± 1.8 4.8 ± 1.4 4.7 ± 1.6 0.011
C reactive protein
(CRP) (mg/dL)
0.6  ± 0.6 0.5 ± 0.4 0.6 ± 0.6 0.4 ± 0.2 0.4 ± 0.3 0.3 ± 0.2 0.2 ± 0.1 0.442
ESR (mm/h) 15.9 ± 12.6 19.9 ± 23.8 9.9 ± 10.7 8.4 ± 5.3 13.4 ± 13.5 10.8 ± 11.3 6.7 ± 4.3 0.021
Microalbuminuria
(mg/L)
5.1 ± 6.8 2.4 ± 3.8 3.7 ± 4.6 2.1 ± 1.6 2.9 ± 4.0 2.3 ± 2.9 2.5 ± 2.7 0.041
HOMA-IR 4.1 ± 2.1 4.3 ± 2.1 3.9 ± 2.7 3.4 ± 2.4 3.0 ± 1.9 3.7 ± 2.7 3.8 ± 3.3 0.894
Cystatin C (mg/L) 0.84 ± 0.24 0.81 ± 0.19 0.79 ± 0.20 0.80 ± 0.18 0.77 ± 0.16 0.76 ± 0.17 0.76 ± 0.18 0.041
CD4 (n) 496.1 ± 213.2 558.6 ± 198.2 502.8 ± 160.6 570.7 ± 165.3 583.6 ± 197.9 598.5 ± 165.5 635.4 ± 161.7 0.018
CD4 (%) 23.8 ± 8.3 25.5 ± 8.5 25.8 ± 9.2 26.5 ± 8.6 27.0 ± 8.5 29.1 ± 7.6 29.8 ± 8.1 <0.001
CD4/CD8 0.6 ± 0.4 0.7 ± 0.4 0.7 ± 0.4 0.7 ± 0.4 0.7 ± 0.4 0.8 ± 0.5 0.8 ± 0.4 <0.001
d by 
C
T
r
1
2
3
4
5
Available online 23 October 2015a Probability that effect of treatment on the SBP and DBP is inﬂuence
onﬂicts  of  interest
he authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s
. Falasca K, Ucciferri C, Teoﬁli L, et al. Short communication:
proangiogenic hematopoietic cells in acute HIV infection. AIDS
Res Hum Retrovir. 2013;29:307–10.
. Vecchiet J, Ucciferri C, Falasca K, Mancino P, Di Iorio A, De
Caterina R. Antihypertensive and metabolic effects of
telmisartan in hypertensive HIV-positive patients. Antivir
Ther. 2011;16:639–45.
. Ucciferri C, Falasca K, Mancino P, Di Iorio A, Vecchiet J.
Microalbuminuria and hypertension in HIV-infected patients: a
preliminary study of telmisartan. Eur Rev Med Pharmacol Sci.
2012;16:491–8.
. Ucciferri C, Falasca K, Mancino P, Pizzigallo E, Vecchiet J.
Proteinuria in an African HIV-infected patient: effects of
telmisartan. Infez Med. 2011;19:125–7.. Falasca K, Ucciferri C, Mancino P, et al. Cystatin C, adipokines
and cardiovascular risk in HIV infected patients. Curr HIV Res.
2010;8:405–10.time. In bold p < 0.05.
Claudio Ucciferri a, Katia Falascaa,∗, Francesca Vignalea,
Marta Di Nicolab, Jacopo Vecchieta
a Clinic of Infectious Diseases, Department of Medicine and Sci-
ence of Aging, “G. d’Annunzio” University School of Medicine,
Chieti-Pescara, Italy
b Laboratory of Biostatistics, Department of Experimental and
Clinical Sciences, “G. d’Annunzio” University School of Medicine,
Chieti-Pescara, Italy
∗ Corresponding author at:  Clinic of Infectious Diseases, Depart-
ment of Medicine and Science of Aging, “G. d’Annunzio”
University School of Medicine, Via dei Vestini, 66013 Chieti-
Pescara, Italy.
E-mail address: k.falasca@unich.it (K. Falasca).
Received 20 July 2015
Accepted 8 August 2015http://dx.doi.org/10.1016/j.bjid.2015.08.012
1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.
